following a re-submission considered under the orphan process
aztreonam lysine (Cayston®) is accepted for restricted use within NHS Scotland.
Indication under review: Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older.
SMC restriction: When inhaled colistimethate sodium and inhaled tobramycin are not tolerated or not providing satisfactory therapeutic benefit (measured as ≥2% decline in forced expiratory volume in 1 second [FEV1]).
Aztreonam lysine has demonstrated superiority in improving lung function and respiratory symptoms in one active-controlled study and two 28-day placebo-controlled studies in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of aztreonam lysine. It is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice191KB (PDF)
- Medicine name:
- aztreonam lysine (Cayston)
- SMC ID:
- Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Submission type
- Date advice published
- 12 January 2015